Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Analyst Says West Pharmaceutical Services Is ‘Expensive But For Good Reason’

Stephens upgraded West Pharmaceutical Services (NYSE:WST) from Equal Weight to Over Weight, with a price target of $400, up from $330.…
byVandana Singh
April 11, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Stephens upgraded West Pharmaceutical Services (NYSE:WST) from Equal Weight to Over Weight, with a price target of $400, up from $330.
  • The analyst says, “West Pharma is expensive for a reason (dominant market share, growing end-markets, quality management team), and we are tired of using valuation as an excuse, especially as there are potential upside drivers to numbers in coming years.”
  • The company has a 70% share in the rubber containment (plungers/stoppers) market, representing a small cost vs. the price of a drug. WST has a long quality track record.
  • The shift to HVP products is driving robust growth as these components cost 30-40+ cents per unit vs. standard products at 1-2 cents. 
  • The company sells into a biologics and injectable drug market, supporting years of stable growth. 
  • The analyst says the stock has admittedly had a strong move already in 2023 and the sentiment has improved for a good reason, as the fundamental outlook is quite positive.
  • Price Action: WST shares are up 1.74% at $355.88 on the last check Tuesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Alterity Therapeutics Announced Monday, Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

By Charles Gross
March 14, 5:36 AM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that the composition of matter patent previously allowed by the United States Patent and Trademark Office (USPTO) has now been granted. The patent, entitled "Compounds for and methods of treating diseases" (No. 11,603,364), covers more than 100 novel compounds with an acyl hydrazone (AH) structure and provides 20 years of exclusivity.

ATHE